vs

Side-by-side financial comparison of Falcon's Beyond Global, Inc. (FBYD) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

Avidity Biosciences, Inc. is the larger business by last-quarter revenue ($12.5M vs $6.6M, roughly 1.9× Falcon's Beyond Global, Inc.). Falcon's Beyond Global, Inc. runs the higher net margin — -4.5% vs -1398.3%, a 1393.8% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs 383.5%). Falcon's Beyond Global, Inc. produced more free cash flow last quarter ($-4.3M vs $-156.9M). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs 108.4%).

500 Global is an early-stage venture fund and seed accelerator founded in 2010 by Dave McClure and Christine Tsai. The fund admitted a first "class" of twelve startups to its incubator office in Mountain View, California in February 2011. They expanded to a second class of 21 in June 2011 and a third class of 34 in October 2011. 500 Global has $2.3 billion in assets under management (AUM) as of March 2024.

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

FBYD vs RNA — Head-to-Head

Bigger by revenue
RNA
RNA
1.9× larger
RNA
$12.5M
$6.6M
FBYD
Growing faster (revenue YoY)
RNA
RNA
+50.6% gap
RNA
434.0%
383.5%
FBYD
Higher net margin
FBYD
FBYD
1393.8% more per $
FBYD
-4.5%
-1398.3%
RNA
More free cash flow
FBYD
FBYD
$152.5M more FCF
FBYD
$-4.3M
$-156.9M
RNA
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
108.4%
FBYD

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
FBYD
FBYD
RNA
RNA
Revenue
$6.6M
$12.5M
Net Profit
$-296.0K
$-174.4M
Gross Margin
Operating Margin
-30.9%
-1513.5%
Net Margin
-4.5%
-1398.3%
Revenue YoY
383.5%
434.0%
Net Profit YoY
97.5%
-117.0%
EPS (diluted)
$-0.01
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FBYD
FBYD
RNA
RNA
Q4 25
$6.6M
Q3 25
$4.1M
$12.5M
Q2 25
$2.5M
$3.8M
Q1 25
$1.7M
$1.6M
Q4 24
$1.4M
$3.0M
Q3 24
$2.1M
$2.3M
Q2 24
$1.8M
$2.0M
Q1 24
$1.5M
$3.5M
Net Profit
FBYD
FBYD
RNA
RNA
Q4 25
$-296.0K
Q3 25
$-10.4M
$-174.4M
Q2 25
$25.1M
$-157.3M
Q1 25
$-8.1M
$-115.8M
Q4 24
$-11.9M
$-102.3M
Q3 24
$39.3M
$-80.4M
Q2 24
$8.0M
$-70.8M
Q1 24
$114.0M
$-68.9M
Operating Margin
FBYD
FBYD
RNA
RNA
Q4 25
-30.9%
Q3 25
-90.9%
-1513.5%
Q2 25
-53.0%
-4448.7%
Q1 25
-371.1%
-8360.9%
Q4 24
-335.6%
-4069.6%
Q3 24
-118.9%
-4200.9%
Q2 24
-195.9%
-4040.4%
Q1 24
-350.5%
-2178.6%
Net Margin
FBYD
FBYD
RNA
RNA
Q4 25
-4.5%
Q3 25
-256.8%
-1398.3%
Q2 25
985.2%
-4089.3%
Q1 25
-473.8%
-7360.0%
Q4 24
-871.7%
-3439.5%
Q3 24
1899.5%
-3441.7%
Q2 24
446.5%
-3461.8%
Q1 24
7521.4%
-1943.4%
EPS (diluted)
FBYD
FBYD
RNA
RNA
Q4 25
$-0.01
Q3 25
$-0.13
$-1.27
Q2 25
$0.30
$-1.21
Q1 25
$-0.13
$-0.90
Q4 24
$-0.25
$-0.80
Q3 24
$0.39
$-0.65
Q2 24
$0.00
$-0.65
Q1 24
$1.27
$-0.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FBYD
FBYD
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$1.9M
$350.2M
Total DebtLower is stronger
$15.6M
Stockholders' EquityBook value
$11.9M
$1.9B
Total Assets
$66.7M
$2.1B
Debt / EquityLower = less leverage
1.31×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FBYD
FBYD
RNA
RNA
Q4 25
$1.9M
Q3 25
$4.3M
$350.2M
Q2 25
$26.1M
$243.9M
Q1 25
$1.1M
$254.2M
Q4 24
$825.0K
$219.9M
Q3 24
$828.0K
$370.2M
Q2 24
$1.7M
$575.8M
Q1 24
$1.1M
$471.4M
Total Debt
FBYD
FBYD
RNA
RNA
Q4 25
$15.6M
Q3 25
Q2 25
Q1 25
Q4 24
$41.2M
Q3 24
$10.3M
Q2 24
$15.7M
Q1 24
$15.1M
Stockholders' Equity
FBYD
FBYD
RNA
RNA
Q4 25
$11.9M
Q3 25
$9.2M
$1.9B
Q2 25
$414.0K
$1.2B
Q1 25
$-11.6M
$1.3B
Q4 24
$-9.0M
$1.4B
Q3 24
$-1.4M
$1.5B
Q2 24
$-44.7M
$1.2B
Q1 24
$-61.7M
$830.9M
Total Assets
FBYD
FBYD
RNA
RNA
Q4 25
$66.7M
Q3 25
$66.8M
$2.1B
Q2 25
$89.2M
$1.4B
Q1 25
$56.7M
$1.5B
Q4 24
$61.2M
$1.6B
Q3 24
$66.5M
$1.6B
Q2 24
$65.9M
$1.3B
Q1 24
$67.8M
$951.5M
Debt / Equity
FBYD
FBYD
RNA
RNA
Q4 25
1.31×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FBYD
FBYD
RNA
RNA
Operating Cash FlowLast quarter
$-4.3M
$-156.2M
Free Cash FlowOCF − Capex
$-4.3M
$-156.9M
FCF MarginFCF / Revenue
-66.0%
-1257.6%
Capex IntensityCapex / Revenue
0.3%
5.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FBYD
FBYD
RNA
RNA
Q4 25
$-4.3M
Q3 25
$-13.3M
$-156.2M
Q2 25
$-7.9M
$-199.7M
Q1 25
$945.0K
$-124.8M
Q4 24
$-3.8M
$-99.9M
Q3 24
$-2.4M
$-65.6M
Q2 24
$-2.6M
$-65.0M
Q1 24
$-3.8M
$-70.4M
Free Cash Flow
FBYD
FBYD
RNA
RNA
Q4 25
$-4.3M
Q3 25
$-13.4M
$-156.9M
Q2 25
$-203.0M
Q1 25
$853.0K
$-128.6M
Q4 24
$-3.8M
$-103.8M
Q3 24
$-2.4M
$-67.3M
Q2 24
$-2.6M
$-65.5M
Q1 24
$-3.8M
$-71.3M
FCF Margin
FBYD
FBYD
RNA
RNA
Q4 25
-66.0%
Q3 25
-329.6%
-1257.6%
Q2 25
-5277.1%
Q1 25
49.9%
-8174.3%
Q4 24
-278.7%
-3491.0%
Q3 24
-114.9%
-2881.8%
Q2 24
-145.6%
-3204.6%
Q1 24
-248.8%
-2012.3%
Capex Intensity
FBYD
FBYD
RNA
RNA
Q4 25
0.3%
Q3 25
1.0%
5.7%
Q2 25
0.0%
86.9%
Q1 25
5.4%
238.6%
Q4 24
0.1%
131.7%
Q3 24
0.2%
72.9%
Q2 24
0.1%
26.0%
Q1 24
0.3%
25.8%
Cash Conversion
FBYD
FBYD
RNA
RNA
Q4 25
Q3 25
Q2 25
-0.31×
Q1 25
Q4 24
Q3 24
-0.06×
Q2 24
-0.33×
Q1 24
-0.03×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons